# Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1

> **NCT05030441** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 20 (actual)

## Conditions studied

- Clonal Cytopenia of Undetermined Significance

## Interventions

- **DRUG:** Ivosidenib

## Key facts

- **NCT ID:** NCT05030441
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-01
- **Primary completion:** 2030-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030441, "Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05030441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*